Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2014

View Archived Issues

Kinetic analysis of the new PET ligand [11C]Lu-AE-92686

ProteoTech given FDA orphan drug status for AL amyloidosis candidate

RetroSense Therapeutics gene therapy gains FDA orphan drug status for retinitis pigmentosa

RadioMedix and Viewpoint Molecular Targeting receive grant for melanoma theranostics

iBio expands collaboration with Novici Biotech

Bavarian Nordic expands collaboration with Janssen on MVA-BN

GlaxoSmithKline reviews pipeline progress of third quarter 2014

VSV-ZEBOV Ebola vaccine candidate begins phase I study at NIAID

Serum bilirubin: a prognostic marker in primary sclerosing cholangitis

Phase III data from GEMINI trials presented for vedolizumab

First-in-human results presented for radiolabeled antibody [68Ga]ABY-025

Vitae Pharmaceuticals reports phase I results for BI-1181181/VTP-37948

The Walter Reed Army Institute discloses new agents for malaria

Novel GPR120 modulators divulged by Bristol-Myers Squibb

SHIELD 4 phase III data presented for vercirnon in patients with Crohn's disease

Sutro Biopharma and Celgene expand agreement for ADCs in immuno-oncology

U.S. group designs novel agents for depression and Parkinson's disease

Sumitomo Dainippon Pharma discloses novel RIO kinase 2 inhibitors

Bristol-Myers Squibb prepares novel agents for HIV infection

Stellar Biotechnologies agrees to supply KLH for BiovaxID

CTI BioPharma acquires worldwide rights to phase II cancer agent tosedostat

FDA sends CRL to Lundbeck regarding intravenous carbamazepine NDA

FDA approves Baxter's Obizur for acquired hemophilia A

CHMP adopts positive opinion for oxycodone/naloxone in RLS

CHMP recommends expanding approval of enzalutamide

EMA committee backs approval of olaparib in BRCA-mutated ovarian cancer

EMA recommends that Clinuvel's Scenesse be approved for EPP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...